NCT07656142 A Personalized Mobile Application Providing Temperature-Related Health Risk Warnings and Protective Recommendations for Patients With Chronic Obstructive Pulmonary Disease
| NCT ID | NCT07656142 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tiantian Li |
| Condition | Chronic Obstructive Pulmonary Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 240 participants |
| Start Date | 2026-08-04 |
| Primary Completion | 2027-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 240 participants in total. It began in 2026-08-04 with a primary completion date of 2027-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will test whether a personalized mobile application that provides temperature-related health risk warnings and protective recommendations can reduce acute exacerbations in people with chronic obstructive pulmonary disease (COPD). Researchers will compare participants who receive the mobile application in addition to usual care with those who receive usual care alone. The main question is whether the mobile application reduces the number of COPD acute exacerbation events over 12 months. The study will also evaluate secondary outcomes including quality of life, functional capacity, symptoms, psychological status, physiological and biochemical indicators, environmental temperature risk perception, and participants' use of the mobile application.
Eligibility Criteria
Hospital inclusion criteria: 1. Tertiary hospitals; 2. Hospitals with respiratory wards that admit patients with COPD; 3. Hospitals with a well-established electronic health record system and follow-up capability; 4. Hospitals able to assign a study coordinator. Patient inclusion criteria: 1. Age \>=40 years and \<=80 years, with no restriction on sex; 2. Patients with stable chronic obstructive pulmonary disease; 3. At least 1 severe acute exacerbation requiring hospitalization, or at least 2 moderate acute exacerbations requiring outpatient or emergency care, within the previous year; 4. Local permanent residents with a duration of residence \>=6 months; 5. Patients who voluntarily agree to participate, are expected to have good adherence, are able to sign informed consent; 6. Patients who own a smartphone or other smart device. Hospital exclusion criteria: 1. Primary hospitals or private hospitals; 2. Hospitals unable to cooperate with the study protocol. Patient exclusion criteria: 1. Patients with asthma; 2. Women who are known to be pregnant or breastfeeding, or who have a positive pregnancy test before cluster randomization; 3. Patients with other diseases that may affect participation in the trial, such as refractory hypertension or severe aphasia; 4. Patients currently receiving psychiatric or psychological treatment that may contaminate study results; 5. Expected survival time \<1 year, such as in those with malignant tumors or severe cardiopulmonary disease; 6. Participation in other interventional clinical studies that may affect outcome assessment; 7. Any other circumstances in which the investigator considers the patient unsuitable for participation in this study or at significant risk, such as cognitive impairment preventing understanding of and/or compliance with study procedures and/or follow-up.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07656142 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 80 Years, studying Chronic Obstructive Pulmonary Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07656142 currently recruiting?
Yes, NCT07656142 is actively recruiting participants. Contact the research team at zhangcan@nieh.chinacdc.cn for enrollment information.
Where is the NCT07656142 trial being conducted?
This trial is being conducted at Beijing, China, Beijing, China, Beijing, China, Beijing, China.
Who is sponsoring the NCT07656142 clinical trial?
NCT07656142 is sponsored by Tiantian Li. The trial plans to enroll 240 participants.